Is American Well (AMWL) Outperforming Other Medical Stocks This Year?
Here is how American Well Corporation (AMWL) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Are Medical Stocks Lagging American Well (AMWL) This Year?
Here is how American Well Corporation (AMWL) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
American Well (AMWL) Is Attractively Priced Despite Fast-paced Momentum
American Well (AMWL) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Is American Well (AMWL) Stock Outpacing Its Medical Peers This Year?
Here is how American Well Corporation (AMWL) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Best Health & Fitness Stocks to Buy Now for Strong Growth
GRMN, HLF and AMWL stand out in a booming wellness market as wearables, nutrition products and telehealth platforms reshape how consumers pursue healthier lives.
Fast-paced Momentum Stock American Well (AMWL) Is Still Trading at a Bargain
American Well (AMWL) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
American Well Corporation (AMWL) Q4 2025 Earnings Call Transcript
American Well Corporation (AMWL) Q4 2025 Earnings Call Transcript
American Well (AMWL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for American Well (AMWL) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
American Well Corporation (AMWL) Q3 2025 Earnings Call Transcript
American Well Corporation ( AMWL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Ido Schoenberg - Chairman & CEO Mark Hirschhorn - Executive VP, COO & CFO Conference Call Participants Stanislav Berenshteyn - Wells Fargo Securities, LLC, Research Division Charles Rhyee - TD Cowen, Research Division Jenny Cao - Truist Securities, Inc., Research Division Jack Senft - UBS Investment Bank, Research Division John Park - Morgan Stanley, Research Division Presentation Operator " Ido Schoenberg Chairman & CEO " Mark Hirschhorn Executive VP, COO & CFO " Stanislav Berenshteyn Wells Fargo Securities, LLC, Research Division " Wells Fargo Securities, LLC, Research Division Charles Rhyee TD Cowen, Research Division " TD Cowen, Research Division Jenny Cao Truist Securities, Inc., Research Division " Truist Securities, Inc., Research Division Jack Senft UBS Investment Bank, Research Division " UBS Investment Bank, Research Division John Park Morgan Stanley, Research Division " Morgan Stanley, Research Division Operator Hello, everyone, and welcome to Amwell's conference call to discuss their third fiscal quarter of 2025. Joining us on the call today are Amwell's Chairman and CEO, Dr. Ido Schoenberg; and Mark Hirschhorn, Amwell's CFO and Chief Operating Officer.
Compared to Estimates, American Well (AMWL) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for American Well (AMWL) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
From Apps to Nutrition: Health & Fitness Stocks to Buy Now
UNFI, AMWL, STKL, and PTON stand out as health and fitness plays, tapping into booming demand for wellness, nutrition and digital care.
American Well Q2 Review: Hold Rating Maintained Amid DHA Renewal Concerns
American Well's revenue growth and cost control are strong, but the short DHA contract extension raises concerns about long-term stability and reliability of key revenue streams. Amwell's shift to higher-margin software revenue is promising, but guidance was revised downward due to contract uncertainties and program exclusions. Cost reductions have improved EBITDA and cash flow outlook, but excessive cuts risk undermining R&D, marketing, and future growth potential.
